Idera Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rose more than 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 24.6% in the past one-month time frame.

The stock gained after the company reported encouraging Phase 1/2 trial data for Intratumoral IMO-2125 in combination with Ipilimumab.

The company has seen no estimate revisions over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Idera Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.  

A better-ranked stock in the Medical - Biomedical and Genetics is Akari Therapeutics PLC (AKTX Quick QuoteAKTX - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is IDRA going up? Or down? Predict to see what others think: Up or Down

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>